List view / Grid view
The FDA has accepted priority review of epcoritamab for adults with relapsed/refractory large B-cell lymphoma, which could be the first subcutaneous bispecific antibody for large B-cell lymphoma.
AbbVie's marketing application for epcoritamab in adults with relapsed/refractory diffuse large B-cell lymphoma has been validated by the European Medicines Agency.
4 April 2017 | By Niamh Marriott, Junior Editor
Janssen Biotech has decided not to initiate stage 2 of the Phase II study of daratumumab in three types of relapsed or refractory non-Hodgkin’s lymphoma...
17 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Genmab’s daratumumab (darazalex) will be investigated in a Phase III clinical study in combination with carfilzomib (kyprolis) and dexamethasone...
12 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The FDA has assigned a prescription drug user fee act (PDUFA) target date of February 17, 2017 to take a decision on daratumumab in this indication...
31 August 2016 | By Niamh Louise Marriott, Digital Content Producer
Approval is supported by the Phase III complement study that evaluated ofatumumab in combination with FC versus FC alone in patients with relapsed CLL...
20 February 2015 | By Genmab
Genmab A/S has entered a co-development and commercialisation agreement with BioNovion to evaluate a number of DuoBody product candidates targeting immune checkpoints...
4 February 2015 | By Genmab
Genmab A/S today announced preliminary results from the Phase II study of daratumumab in double refractory multiple myeloma conducted by its collaboration partner Janssen Biotech...
10 November 2014 | By Genmab A/S
Genmab A/S announced today that the French Intergroup of Myeloma (IFM) in collaboration with Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and Janssen Biotech, Inc. plans to start an additional Phase III study of daratumumab in frontline multiple myeloma...
4 October 2013 | By GlaxoSmithKline
GlaxoSmithKline plc and Genmab announced the submission of a variation to the Marketing Authorisation to the European Medicines Agency (EMA) for the use of Arzerra...
